Subscribe to Search results

At a Haemophilia Reference Centre Directors meeting, Professor Edward Blackburn observed that "It seems that the Radio and Television authorities have the right to edit and comment on their presentations as they think fit."

Published on:

Dr Craske produced a report of the Haemophilia Directors Hepatitis Working Party, which presented evidence of specific protection conferred by a previous batch of Hemofil against contracting Non-A Non-B Hepatitis.

Published on:

In a Haemophilia Centre Directors' Hepatitis Working Party report, Dr Craske concluded that "there remains much work to be done to devise methods to prevent the threat of chronic liver disease clouding the undoubted benefits that large pool concentrates have brought."

Published on:

Dr Brian Colvin described in his oral evidence some clinicians' belief that Non-A Non-B Hepatitis was benign as "wishful thinking".

Published on:

Dr Brian Colvin confirmed that, by 1975, the haemophilia treating community was aware that there was at least a possibility of chronic liver disease in haemophilia.

Published on:

Dr Brian Colvin told the Inquiry he treated very small children with cryoprecipitate until the mid 1980s.

Published on:

Dr Brian Colvin told the Inquiry that around 1982-1983 he was using a significant quantity of commercial concentrate in the hospital due to shortfall in NHS concentrate.

Published on:

In a Haemophilia Centre Directors' Hepatitis Working Party meeting, Dr Kirk described the results of the prospective survey on hepatitis carried out at Edinburgh and Alton, which show a higher proportion of patients treated with freeze dried products who had consistently abnormal liver enzyme tests, compared with the boys treated with cryoprecipitate.

Published on:

In a Haemophilia Centre Directors' Hepatitis Working Party meeting, it was agreed that the NHS Factor 8 associated hepatitis study should start on 1 June 1978.

Published on:

Haemophilia centre directors agreed in principle that it was a good idea for patients to be kept on one type (or preferably one batch) of concentrate for long periods.

Published on:

Dr Craske requested haemophilia centre directors send in details of cases of chronic hepatitis on a new form which the Haemophilia Centre Directors' Working Party would draw up and distribute to centres.

Published on:

The reason for the DHSS' suggestion that patients be kept on one type or one batch of concentrate was to simplify analysis and presentation of results, increase the chances of identifying icterogenic material and permit the withdrawal of icterogenic bottles.

Published on:

Dr Craske wrote to the Small Grants Secretariat recording that whilst haemophilia centre directors had agreed in theory to maintaining patients on single batches or brands, the shortage of Factor VIII, large numbers of patients under treatment and the cost of maintaining stocks of Factor VIII meant that they did not consider it to be a practical policy to stick rigidly to this regime.

Published on:

Dr Mary Collins on behalf of the DHSS said regarding self-sufficiency that there was no limit on the amount of commercial material which Haemophilia Centres could receive.

Published on:

In a meeting of the haemophilia centre directors, it was reported that the 1976 and 1977 annual returns from haemophilia centres demonstrated that an increasingly large amount of commercial Factor 8 concentrate was being used by centres.

Published on:

The Hepatitis Working Party agreed to continue the study on the Oxford Haemophiliacs to obtain more evidence of the relationship of transaminitis and overt chronic liver disease to mortality.

Published on:

There was little discussion of issues relating to hepatitis at the haemophilia reference centre directors'

Published on:

Dr Craske gave a presentation on the work of the Hepatitis Working Party at the UKHCDO annual meeting

Published on:

The Hepatitis Working Party agreed more information was needed on the risk to patients of developing chronic NANBH, by prospectively following patients first exposed to concentrate or other products, such as people with mild haemophilia undergoing non-emergency surgery.

Published on:

Dr Peter Jones became director of the Newcastle Haemophilia Centre.

Published on: